The gut microbiome is emerging as an important contributor to drug pharmacokinetics and pharmacodynamics interacting with drugs by directly metabolizing them, indirectly affecting host drug-metabolizing enzymes, and modifying the response to drugs

We summarize clinically important interactions between the gut microbiota and several drugs such as digoxin, irinotecan, immune checkpoint inhibitors, levodopa, and non-steroidal anti-inflammatory drugs